GLP-1 analog fusion protein formulations

Details for Australian Patent Application No. 2005319432 (hide)

Owner Eli Lilly and Company

Inventors Glaesner, Wolfgang; Millican, Rohn Lee Junior

Agent Spruson & Ferguson

Pub. Number AU-A-2005319432

PCT Pub. Number WO2006/068910

Priority 60/641,690 22.12.04 US

Filing date 15 December 2005

Wipo publication date 29 June 2006

International Classifications

C07K 14/50 (2006.01) Peptides having more than 20 amino acids

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/26 (2006.01) Medicinal preparations containing peptides - Glucagons

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07K 14/435 (2006.01) Peptides having more than 20 amino acids - from animals

C07K 14/605 (2006.01) Peptides having more than 20 amino acids

C12N 15/62 (2006.01) Mutation or genetic engineering - DNA sequences coding for fusion proteins

Event Publications

17 May 2007 PCT application entered the National Phase

  PCT publication WO2006/068910 Priority application(s): WO2006/068910

12 July 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005319441-A method of hydroponic cultivation and components for use therewith

2005319427-Rapamycin derivatives and the uses thereof in the treatment of neurological disorders